Dylan Dupuis
Stock Analyst at Roth MKM
(3.38)
# 838
Out of 4,667 analysts
9
Total ratings
44.44%
Success rate
34.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dylan Dupuis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMMB Chemomab Therapeutics | Reinstates: Buy | $7 | $1.64 | +326.83% | 2 | Dec 19, 2023 | |
| IVA Inventiva | Reiterates: Buy | $11 | $2.74 | +301.46% | 2 | Sep 21, 2023 | |
| TERN Terns Pharmaceuticals | Reiterates: Buy | $23 | $5.60 | +310.71% | 3 | Aug 8, 2023 | |
| VKTX Viking Therapeutics | Assumes: Buy | $32 | $51.53 | -37.90% | 1 | May 31, 2023 | |
| UBX Unity Biotechnology | Initiates: Buy | $10 | $1.17 | +754.70% | 1 | May 31, 2023 |
Chemomab Therapeutics
Dec 19, 2023
Reinstates: Buy
Price Target: $7
Current: $1.64
Upside: +326.83%
Inventiva
Sep 21, 2023
Reiterates: Buy
Price Target: $11
Current: $2.74
Upside: +301.46%
Terns Pharmaceuticals
Aug 8, 2023
Reiterates: Buy
Price Target: $23
Current: $5.60
Upside: +310.71%
Viking Therapeutics
May 31, 2023
Assumes: Buy
Price Target: $32
Current: $51.53
Upside: -37.90%
Unity Biotechnology
May 31, 2023
Initiates: Buy
Price Target: $10
Current: $1.17
Upside: +754.70%